Discontinued — last reported Q4 '24
Olumiant — Revenue
Eli Lilly Olumiant — Revenue increased by 4.3% to $261.50M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 7.4%, from $243.40M to $261.50M. Over 3 years (FY 2021 to FY 2024), Olumiant — Revenue shows a downward trend with a -5.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing market adoption or successful expansion into new indications, while a decrease may signal increased competition, patent expirations, or loss of market share.
Detailed definition
This metric represents the total gross sales generated by the specific pharmaceutical product line within the company's...
Peer comparison
Comparable to product-level revenue reporting in other major pharmaceutical companies, often benchmarked against therapeutic area peers.
lly_segment_olumiant_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $208.40M | $406.90M | $306.00M | $255.60M | $186.20M | $182.90M | $205.80M | $228.90M | $218.90M | $231.40M | $243.40M | $217.40M | $227.70M | $250.80M | $261.50M |
| QoQ Change | — | +95.2% | -24.8% | -16.5% | -27.2% | -1.8% | +12.5% | +11.2% | -4.4% | +5.7% | +5.2% | -10.7% | +4.7% | +10.1% | +4.3% |
| YoY Change | — | — | — | — | -10.7% | -55.1% | -32.7% | -10.4% | +17.6% | +26.5% | +18.3% | -5.0% | +4.0% | +8.4% | +7.4% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's olumiant — revenue?
- Eli Lilly (LLY) reported olumiant — revenue of $261.50M in Q4 2024.
- How has Eli Lilly's olumiant — revenue changed year-over-year?
- Eli Lilly's olumiant — revenue increased by 7.4% year-over-year, from $243.40M to $261.50M.
- What is the long-term trend for Eli Lilly's olumiant — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's olumiant — revenue has grown at a -5.0% compound annual growth rate (CAGR), from $1.12B to $957.40M.
- What does olumiant — revenue mean?
- The total revenue generated from sales of the specific pharmaceutical product.